MedTrace Logo

Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer

NCT02258165 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2023-04-18

No results posted yet for this study

Summary

This study will be the first prospective study enrolling consecutive patients with advanced ovarian cancer to determine the prevalence of thoracic and extra-abdominal involvement in this patient group and the relative value of gated PET and CT for diagnosing extra-abdominal involvement. This study will also answer a number of other stil unanswered questions: the impact of gating and the impact of gated PET on clinical management of patients with advanced ovarian cancer. This study also individualises patients' treatment to allow patients who may benefit most form optimal surgical cytoreduction and those who are better treated by neoadjuvant

Conditions

  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage IV

Interventions

DEVICE

PET/CT

PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By "freezing" this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images.

Sponsors & Collaborators

  • The University of Queensland

    collaborator OTHER

  • Royal Brisbane and Women's Hospital

    collaborator OTHER_GOV

  • Queensland Centre for Gynaecological Cancer

    lead OTHER_GOV

Principal Investigators

  • Andreas Obermair · Queensland Centre for Gynaecological Cancer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-10-10
Completion
2022-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02258165 on ClinicalTrials.gov